Our investment in the Xcelodose 120S System underscores Emerson Resources’ rigorous commitment to consistent innovation and superior quality.
Norristown, PA (PRWEB) August 22, 2012
Emerson Resources, Inc., a premier pharmaceutical development company, today announced the acquisition of the Xcelodose 120S Precision Powder Micro-Dosing System, by Capsugel. By implementing this established technology for early stage clinical studies, Emerson Resources expects to accelerate the turnaround of Phase I Clinical Trials and shorten overall drug product development time.
Emerson Resources selected the Xcelodose 120S System for its ability to deliver extremely precise and accurate micro-dosing into capsules. This added capability will enable the Company to achieve increased efficiencies, as well as significantly reduce the need for costly and time-consuming compatibility studies.
Key features and benefits of the technology include:
- Highly consistent dose accuracy – Delivers precise, automated dispensing of dose weights as low as 100 micrograms, which can be difficult to formulate accurately with traditional means.
- Filling API in capsule – Simplifies analytical methods, reduces waste and limits the need for extensive drug product development. Typically, additional product development is required for products that are developed with other solid dose formulations.
- CFR 211 Compliant - Automated and secure data capture, provides traceability for cGMP requirements.
“Our investment in the Xcelodose 120S System underscores Emerson Resources’ rigorous commitment to consistent innovation and superior quality,” said Adolfo Gomez, President of Emerson Resources. “This vital addition to our cutting-edge facility will notably impact our ability to streamline the process of preparing product for clinical trials, reduce project costs, and exceed our already exceptional levels of customer service.”
Leading pharmaceutical companies across the United States and around the world rely on Emerson Resources for its expertise in drug development, clinical supplies manufacturing, cGMP documentation, and analytical development and testing. The Company’s pilot plant, located in Norristown, Pennsylvania, is certified Class 100,000/ISO 8 for manufacturing Phase I–II clinical supplies.
For more information about Emerson Resources visit http://www.emersonresources.com.
About Emerson Resources
Emerson Resources’ reputation as a dependable, dynamic, flexible, and pragmatic organization has been built on the core concepts of excellent service, superb quality and complete client satisfaction. The Emerson mission is to deliver value-added service, ingredients and expertise to the pharmaceutical and biotech industries.
For more information visit http://www.emersonresources.com.